JPRN-C000000303
Unknown
未知
Romdomized study to evaluate the renoprotective effects of clarithromycin for diabetic patients with microalbuminuria. - The study of the renoprotective effects of clarithromycin for diabetic nephropathy.
Okayama university graduate school of medicine, dentistry and pharmaceutical sciences, Department of medicine and clinical science0 sites40 target enrollmentDecember 30, 2005
Overview
- Phase
- 未知
- Intervention
- Not specified
- Conditions
- Not specified
- Sponsor
- Okayama university graduate school of medicine, dentistry and pharmaceutical sciences, Department of medicine and clinical science
- Enrollment
- 40
- Last Updated
- 2 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- Not provided
Exclusion Criteria
- •1\.CHF 2\.Severe liver and/or kidney dysfunction 3\.History of allergic response to drugs
Outcomes
Primary Outcomes
Not specified
Similar Trials
Not yet recruiting
Phase 1
A clinical trial to study the effect of a polyherbomineral drug, Eladi Churna in patients with diabetic kidney disease.Health Condition 1: E112- Type 2 diabetes mellitus with kidney complicationsCTRI/2023/06/054530Dr Jupitora Dutta
Active, not recruiting
Phase 1
This study aims to investigate the potential beneficial effects on the kidney of a new medication called Dapagliflozin in type 2 diabetic patients.EUCTR2013-004042-42-GBKing’s College London40
Completed
Not Applicable
An exploratory clinical study of the renoprotective effect of empagliflozin and the verification of companion diagnostics in type 2 diabetes patientsType 2 diabetes mellitusJPRN-UMIN000023902Department of Applied Molecular Medicine, Niigata University Graduate School of Medical and Dental Sciences51
Active, not recruiting
Phase 1
This study will assess the effects of dapagliflozin (a drug that is used in patients with Type 2 Diabetes) on lowering the level of urine protein in patients with non-diabetic kidney disease.EUCTR2017-001090-16-NLniversity Medical Center Groningen53
Completed
Phase 3
A study to assess the renoprotective effects of the SGLT2 inhibitor Dapagliflozin in non-diabetic patients with proteinuria: a randomized double blind 6-week cross-over trialNL-OMON47662niversitair Medisch Centrum Groningen20